沃华医药(002107) - 2021 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2021 was CNY 252,471,189, representing a 15.79% increase compared to CNY 218,047,533 in the same period last year[8] - Net profit attributable to shareholders was CNY 50,842,995, up 15.20% from CNY 44,134,455 in the previous year[8] - The net profit after deducting non-recurring gains and losses was CNY 50,402,010, a significant increase of 32.49% from CNY 38,041,634 in the same period last year[8] - Basic and diluted earnings per share rose to CNY 0.09, reflecting a 12.50% increase from CNY 0.08 in the same period last year[8] - Total operating revenue for the first quarter reached CNY 252,471,189, an increase from CNY 218,047,533.39 in the previous period[36] - Total operating revenue for Q1 2021 was CNY 175,473,346.29, an increase from CNY 148,657,679.00 in the same period last year, representing a growth of approximately 18%[41] - Net profit for Q1 2021 reached CNY 50,722,586.35, compared to CNY 45,213,931.06 in Q1 2020, reflecting an increase of about 10%[38] - Operating profit for Q1 2021 was CNY 60,284,138.79, compared to CNY 54,077,334.37 in the previous year, marking an increase of around 11%[38] - The total comprehensive income for Q1 2021 was CNY 50,722,586.35, compared to CNY 45,213,931.06 in Q1 2020, indicating an increase of approximately 12%[39] Cash Flow - The net cash flow from operating activities increased by 64.84% to CNY 83,986,583 from CNY 50,951,359 in the previous year[8] - The net cash flow from operating activities for the first quarter was CNY 83,986,583.11, an increase of 64.8% compared to CNY 50,951,359.62 in the previous year[46] - Total cash inflow from operating activities was CNY 298,899,761.79, up from CNY 236,014,746.40, reflecting a growth of 26.5%[46] - The cash outflow from operating activities was CNY 214,913,178.68, compared to CNY 185,063,386.78, representing an increase of 16.2%[46] - Cash and cash equivalents at the end of the period totaled CNY 510,777,278.46, an increase from CNY 428,302,894.08 at the end of the previous year[47] - The company reported a cash outflow of CNY 52,357,433.22 from financing activities, indicating a net cash flow decrease in this segment[47] - The cash inflow from operating activities for the parent company was CNY 197,473,406.39, compared to CNY 159,496,528.18 in the previous year, marking an increase of 23.7%[48] - The net cash flow from the parent company's operating activities was CNY 76,719,196.75, up from CNY 53,292,762.74, reflecting a growth of 43.9%[48] Assets and Liabilities - Total assets at the end of the reporting period were CNY 1,376,936,157.94, a slight increase of 0.50% from CNY 1,370,094,900.45 at the end of the previous year[8] - Net assets attributable to shareholders increased by 6.30% to CNY 858,241,984.72 from CNY 807,398,989.35 at the end of the previous year[8] - Current assets totaled CNY 761,757,316.25, up from CNY 636,659,401.97 at the end of the previous year, indicating a growth of approximately 19.6%[31] - Non-current assets amounted to CNY 377,811,486.58, slightly down from CNY 379,186,440.78, reflecting a decrease of about 0.4%[33] - Total assets increased to CNY 1,139,568,802.83 from CNY 1,015,845,842.75, marking a growth of approximately 12.2%[34] - Total liabilities decreased to CNY 315,853,191.14 from CNY 240,854,186.02, a reduction of about 31.1%[34] - Owner's equity rose to CNY 823,715,611.69, compared to CNY 774,991,656.73, representing an increase of approximately 6.3%[34] Expenses - Management expenses increased by 45.24% to CNY 11,589,930.60, primarily due to higher salaries and depreciation costs[16] - Total operating costs increased to CNY 192,661,702.85 from CNY 171,186,817.05, which is an increase of approximately 12.5%[37] - Sales expenses for Q1 2021 were CNY 113,652,780.34, compared to CNY 101,341,102.02 in the same period last year, reflecting an increase of about 12.3%[37] - Research and development expenses amounted to CNY 12,742,362.92, up from CNY 10,151,208.86, indicating a year-over-year increase of approximately 25.5%[37] Other Information - The company did not engage in any repurchase transactions among the top 10 shareholders during the reporting period[12] - The company reported no securities or derivative investments during the reporting period[19][20] - There were no significant contracts or entrusted financial management activities reported during the period[21][22] - The company has not engaged in any non-operating fund occupation by controlling shareholders or related parties during the reporting period[23] - The company has committed to avoiding competition and regulating related transactions, with specific commitments made by shareholders in 2015[18] - The company has temporarily postponed the acquisition of 29.4% of Nanchang Jisun Pharmaceutical Co., Ltd. due to intensified market competition, as approved in the 2018 annual general meeting[18] - The company has not reported any violations regarding external guarantees during the reporting period[22] - The company did not require adjustments to the initial balance sheet items due to the new leasing standards, as it only has short-term leasing operations[52] - The first quarter report was not audited, which may affect the reliability of the financial data presented[53]